1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This FOA is to develop, improve, and implement laboratory techniques to assess babies born with severe combined immune deficiency (SCID) and other primary immunodeficiencies using next generation sequencing technologies as a second tier test in state newborn screening aboratories. CDC seeks to evaluate the potential of using next generation sequencing technologies in the state newborn screening laboratory setting. Results of this activity will be used to inform other state newborn screening laboratories about the feasibility of using next generation sequencing technologies in the state newborn screening laboratory setting to evaluate babies that screen positive for SCID and other primary mmunodeficiencies. The ultimate goal is to improve treatment outcomes for babies with SCID or other primary immunodeficiencies.
Funding Opportunity Number: RFA-EH-15-002. Assistance Listing: 93.070. Funding Instrument: CA. Category: HL. Award Amount: Up to $350K per award.
Get alerted about grants like this
Save a search for “Centers for Disease Control and Prevention - ERA” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: Others (see text field entitled Additional Information on Eligibility for clarification). State governments,County governments,City or township governments,Special district governmentsIndependent school districts,Public and State controlled institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Native American tribal organizations (other than Federally recognized tribal governments),Nonprofits having a 501(c)(3) status with the IRS, other than institutions ofhigher education,Nonprofits without 501(c)(3) status with the IRS, other than institutions ofhigher education,Private institutions of higher education,For profit organizations other than small businesses,Small businesses,Others (see text field entitled "Additional Information on Eligibility" for clarification),Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Up to $350K per award Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is April 6, 2015. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
The CDC Prevention Epicenters Program has been established to develop, implement and evaluate the effectiveness of epidemiologically-based strategies to improve healthcare quality and patient safety. This funding opportunity announcement is designed to utilize the CDC Prevention Epicenters Program to translate basic, epidemiologic and technologic discoveries into new strategies for improving prevention of HAIs, Antimicrobial resistance (AR) and other adverse events in all types of healthcare facilities in the United States. Funding Opportunity Number: RFA-CK-16-004. Assistance Listing: 93.084. Funding Instrument: CA. Category: HL. Award Amount: $400K – $500K per award.
Lyme disease, caused primarily by the spirochete Borrelia burgdorferi sensu stricto in the United States, is the most commonly reported vector-borne disease with >30,000 confirmed or probable cases reported annually and a recent estimate suggesting that ten-fold more cases may occur. There is currently no human vaccine against B. burgdorferi. However, tick/pathogen control efforts that combine killing of host-seeking ticks with targeting of natural rodent reservoirs for B. burgdorferi can reduce the abundance of host-seeking infected ticks on residential properties. The purpose of the project is to advance knowledge of the impact of protection of single versus multiple adjacent properties - in relation to human landscape use patterns and tick exposure locations – to reduce human exposure to ticks infected with Lyme disease spirochetes. Funding Opportunity Number: RFA-CK-16-002. Assistance Listing: 93.942. Funding Instrument: CA. Category: HL. Award Amount: $100K – $300K per award.
Arthritis affects 52.5 million adults and is the most common cause of disability in the United States, yet it is relatively understudied given its large burden, especially in the African American population. Osteoarthritis of the hip and knee are the most common causes of arthritis disability. As OA continues to grow in prevalence and burden, much more remains to be learned from a public health perspective about its incidence, prevalence, progression, and the factors associated with each. This need has been described in documents such as the 1999 National Arthritis Action Plan - A Public Health Strategy, and is a priority for the CDC Arthritis Program. The need is also documented in the recommendations of the 2010 National Public Health Agenda for Osteoarthritis.The purpose of this funding opportunity announcement is to support a population-based longitudinal study, which is designed to: (1) refine population-based estimates of the prevalence, incidence, and progression of hip and knee osteoarthritis and related outcomes; (2) gather information on and investigate possible factors (both risk and protective, including other chronic conditions) associated with the above outcomes; and (3) determine racial or ethnic differences in outcomes and in the role of comorbid conditions and the effect of risk factors upon osteoarthritis outcomes. Funding Opportunity Number: RFA-DP-16-003. Assistance Listing: 93.283. Funding Instrument: CA. Category: HL. Award Amount: $600K – $1.5M per award.
This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease.The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Ideally, endpoints proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings.This FOA is not intended to support the development of animal and ex vivo model systems for the interrogation of disease etiology or for the identification of new drug targets. It is also not intended to support human clinical validation of model systems or pharmacodynamic markers. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts(IGNITE) focused on enabling the exploratory and early stages of drug discovery. Funding Opportunity Number: RFA-NS-16-013. Assistance Listing: 93.279,93.853. Funding Instrument: G. Category: ED,HL. Award Amount: Up to $250K per award.
Food irradiation is a food preservation method which is used in many countries, both in human and animal food manufacturing. Treating food with irradiation results in large reduction in microbial contamination and insect pests. It is also useful in slowing ripening of fruit and for inhibiting sprouting of plant products. In USA, the FDA regulates all aspects of irradiation, such as irradiation dose, product type, and labeling requirements. The use of irradiation requires development of analytical methods capable to determine the irradiation status of wide variety of foods, in order to ensure that food is properly labeled, as well as to insure that products were properly handled during irradiation process. Current FDA regulations allow a maximum absorbed dose of 50 kGy in animal feed, pet food, and treats that are irradiated to reduce microbial and insect pest contamination. There are however, very few tests, with limited application, to quantify the actual dose used when irradiating animal food products. Depending on the type of food, various methods are available to detect food irradiation. For fatty foods, the major methods are based on chemical determination of compounds formed from the irradiation of lipids (hydrocarbons and 2-alkylcyclobutanones). It is believed that 2-alkylcyclobutanones (2-ACBs) are formed in food only by irradiation, and they are considered as markers for detecting the irradiation in food. Electron spin resonance (ESP) spectroscopy detects irradiation induced paramagnetic centers (e.g. radicals). This method is applicable for detection of irradiated foods containing bone, cellulose or crystalline sugar. Thermoluminescence is a method applicable to those foods from which a sufficient amount of silicate minerals can be isolated. Photostimulated luminescence is a different method, which can be applied to detect irradiation of any food which contains mineral debris. DNA comet assay can be used to detect irradiation of any food containing DNA, with several limitations. Different microbiological methods are also available, but can only be used as a screening tool.The current funding opportunity is designed to develop analytical methods for detection and quantification of markers such as 2-ACB's in animal feeds and treats to help the FDA to determine and regulate the dose of irradiation that was used during production. Eligibility is limited to domestic (U.S) applicants. Funding Opportunity Number: PAR-16-132. Assistance Listing: 93.103. Funding Instrument: CA. Category: AG,CP,FN. Award Amount: Up to $99K per award.